Key Highlights
- Oncolytics Biotech shares traded at $0.85, down 0.39% on the day.
- The FDA granted fast-track designation to the GOBLET trial, noted July 20, 2026.
- The trial evaluates pelareorep and mFOLFIRINOX with and without atezolizumab in colorectal and advanced anal cancers.
- Prior Phase 1/2 data reported an overall response rate of approximately 29%.
Oncolytics Biotech Inc. (NASDAQ: ONCY) shares traded at $0.85, down 0.39% on the day, after the FDA granted fast-track designation to the company's GOBLET trial, evaluating pelareorep and mFOLFIRINOX with and without atezolizumab in colorectal and advanced anal cancers.
What Happened
The fast-track designation was noted July 20, 2026, and follows a Type C meeting scheduled with the FDA on April 16, 2026.
Phase 1/2 data from the trial, presented at AACR on April 17-22, 2026, and updated data noted January 12, 2026, reported an overall response rate of approximately 29%.
Market Reaction
Shares traded roughly flat, down 0.39% at $0.85, with Oncolytics Biotech's market capitalization at approximately $101.45 million, according to the disclosed pipeline database.
The muted share price reaction contrasts with the regulatory significance of a fast-track designation, which is typically intended to facilitate development and expedite review of drugs addressing serious conditions with unmet medical need.
Outlook
The fast-track designation may facilitate more frequent communication with the FDA as the GOBLET trial progresses; the disclosed information does not include specific next steps beyond the designation itself.
What did the FDA grant to Oncolytics Biotech's GOBLET trial?
The FDA granted fast-track designation, noted July 20, 2026.
What is the GOBLET trial evaluating?
It is evaluating pelareorep and mFOLFIRINOX, with and without atezolizumab, in colorectal and advanced anal cancers.
What has prior GOBLET trial data shown?
Phase 1/2 data reported an overall response rate of approximately 29%.






Please wait processing your request...